Maitake D-Fraction and MD-Fraction are standardized beta-glucan extracts from Grifola frondosa shown to activate NK cells, macrophages, and T cells through Dectin-1 receptor signaling. In a Phase I/II breast cancer trial, immune cell activity increased up to 50% at the highest dose, according to research published in the Journal of Cancer Research and Clinical Oncology.
What Are D-Fraction and MD-Fraction?
D-Fraction and MD-Fraction are the two most studied standardized extracts from maitake mushroom. They're not the same thing. D-Fraction is a beta-1,3/1,6-glucan complex isolated from Grifola frondosa fruiting bodies, while MD-Fraction features a beta-1,6 backbone with beta-1,3 branches — a structural difference that affects how each fraction interacts with immune receptors. Both are meaningfully more concentrated than whole maitake powder, which delivers far lower beta-glucan levels than the standardized extracts used in clinical trials.
The distinction matters practically. In the 2002 cancer case series published in Alternative Medicine Review, whole maitake powder combined with MD-Fraction outperformed either alone — suggesting the fractions and the whole mushroom work through complementary mechanisms rather than identical ones. Extraction and standardization are what make these compounds measurable and reproducible across studies.
Maitake (hen-of-the-woods) grows at the base of oak trees in temperate forests. Its unusually high beta-glucan density compared to other edible fungi is what made it the subject of sustained immunological research beginning in the 1980s with Dr. Hiroaki Nanba's initial D-Fraction isolation work.
How Maitake Beta-Glucan Activates the Immune System
Beta-glucans from maitake bind Dectin-1 receptors on macrophages and dendritic cells. A 2021 meta-analysis of 24 preclinical studies published in the Journal of Ethnopharmacology found that maitake polysaccharide elevated IL-12 by a mean difference of 35.95 and TNF-α by 10.03, with CD4+ T cell percentage rising by 3.03 — all statistically significant at p<0.01.
The cascade works like this. Dectin-1 binding triggers Syk kinase, which activates NF-kB transcription factors inside the immune cell. NF-kB then drives production of pro-inflammatory cytokines: TNF-α, IL-12, IL-2, and IFN-γ. These cytokines don't just circulate — they prime NK cells and cytotoxic CD8+ T cells for target recognition and killing. It's a coordinated upstream activation, not a single-receptor effect.
Dendritic cells respond particularly strongly. A 2024 study published in Acta Pharmacologica Sinica found that the maitake beta-glucan GFPBW1 increased dendritic cell CD80 expression by 70.4% at 50 μg/mL and drove TNF-α secretion up 49.28-fold at higher concentrations. That level of antigen-presenting cell maturation has direct implications for adaptive immunity — it's the mechanism behind maitake's emerging role as a potential vaccine adjuvant.
Clinical Evidence: What Human Trials Actually Show
The strongest human data comes from two trials. A Phase I/II breast cancer trial (n=34) found a statistically significant association between maitake polysaccharide extract and immunological function (p<0.0005), with CD3+CD56+ NK T cells and CD4+CD25+ regulatory T cells each increasing approximately 50% at the highest dose of 10 mg/kg/day, according to results published in the Journal of Cancer Research and Clinical Oncology.
The second trial examined myelodysplastic syndrome (MDS) — a bone marrow condition that impairs immune cell production. In a Phase II study (n=21, 12 weeks, 3 mg/kg twice daily), monocyte ROS production in response to E. coli stimulation improved by 10.4 units (p=0.0004), and neutrophil ROS increased 3.2 units (p=0.005). No serious adverse events were observed. These are meaningful functional improvements in patients whose immune systems are compromised by the underlying disease.
The MD-Fraction cancer case series (Nanba, 2002) adds observational data: symptom regression or improvement occurred in 68.8% of breast cancer patients, 62.5% of lung cancer patients, and 58.3% of liver cancer patients. This wasn't a randomized controlled trial — it was a case series, with all the limitations that implies. But the consistency of the pattern across cancer types is notable, and it's the figure most frequently cited in integrative oncology literature.
In the 2002 MD-Fraction case series, immune-competent cell activity was enhanced 1.2 to 1.4 times when maitake was combined with chemotherapy versus chemotherapy alone. That modest but consistent synergistic signal has driven the current wave of combination therapy research. Source: PubMed PMID 12126464.
The MDSC Mechanism: Reversing Immune Suppression in Tumors
One of the most significant recent findings concerns myeloid-derived suppressor cells (MDSCs). A 2024 study published in the International Journal of Biological Sciences found that GFP polysaccharide reduced splenic MDSCs from 61.3% (tumor control) to 18.2% in the high-dose group — a roughly 70% reduction that corresponded with tumor inhibition rates of 22.26% (low dose), 50.56% (medium dose), and 77.65% (high dose).
MDSCs are a core mechanism by which tumors escape immune surveillance. They accumulate in the spleen and tumor microenvironment, suppress CD8+ cytotoxic T cell activity, and prevent NK cell infiltration. When GFP eliminated them, Granzyme B — a key marker of cytotoxic T cell killing activity — was significantly upregulated (p=0.0002). The researchers identified 1,018 differentially expressed genes in treated versus control tumors.
This mechanism also explains why intermediate doses sometimes show stronger functional responses than the highest doses in some studies. High-dose protocols appear to drive phenotypic shifts in immune cell populations, while intermediate doses favor functional activation — a distinction the Phase I/II breast cancer trial also observed.
Synergy with Conventional Cancer Treatments
The most clinically actionable research isn't maitake alone — it's maitake combined with conventional treatment. A 2023 study in Molecules found that a Grifola frondosa polysaccharide-protein complex combined with cyclophosphamide achieved 65.29% tumor inhibition versus 24.82% for cyclophosphamide alone, with IFN-γ increasing 2.13-fold and TNF-α 2.03-fold compared to the chemotherapy-only group.
The 2024 trastuzumab study (Biological and Pharmaceutical Bulletin) adds a targeted therapy angle. MD-Fraction enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) when combined with trastuzumab in HER2-positive breast cancer models. NK cells showed enhanced trastuzumab-induced killing, and C3a complement activation was dose-dependent. This suggests MD-Fraction may amplify the immune-engaging mechanisms of monoclonal antibody therapies, not just cytotoxic chemotherapy.
A 2024 study found that GFPBW1 beta-glucan as a vaccine adjuvant produced anti-OVA antibody serum titers of 1:409,600 versus 1:6,400 for antigen alone — a 64-fold increase — and achieved 100% tumor prevention in a prophylactic model at 50 and 300 μg doses. Source: PMC11489655.
The NK cell thymus index also rose 1.90 times in the combination cyclophosphamide group compared to controls, suggesting maitake may partially offset the immunosuppressive effects of chemotherapy on lymphoid organs. This is the combination signal that integrative oncology clinics have been acting on since the early case series data — now with substantially more mechanistic grounding.
Safety Profile, Interactions, and Dosing Context
In the Phase I/II breast cancer trial, no dose-limiting toxicity was encountered at doses up to 10 mg/kg/day. Grade 1 adverse events were reported — nausea, joint swelling, rash, and pruritus — and two of 34 patients withdrew. The MDS Phase II trial reported asymptomatic eosinophilia in four of 21 patients, which resolved without intervention. The overall tolerability profile across clinical studies is favorable.
Two drug interactions require attention. Maitake can elevate INR in patients taking warfarin, requiring monitoring and dose adjustment. It also has an additive blood-glucose-lowering effect when combined with diabetes medications, which can lead to hypoglycemia if not managed. These aren't theoretical concerns — they're the interactions most commonly flagged by integrative pharmacology resources including Memorial Sloan Kettering's herb database.
Maitake isn't recommended during pregnancy or lactation due to insufficient safety data. Immunosuppressed patients and organ transplant recipients should consult a physician before use, as the immune-activating effects of D-Fraction and MD-Fraction could theoretically interfere with immunosuppressive therapy regimens. Source: MSKCC Herb Summary.
On dosing: the standardized extracts used in clinical trials are not equivalent to whole maitake powder supplements or functional food products. The concentrations that produced measurable immunological effects in trials — 3–10 mg/kg/day of purified polysaccharide extract — are significantly higher than what most commercial capsule products deliver. If you're looking at maitake dosage guidance, understanding this distinction between extract and whole powder is the starting point.
What the Research Can and Cannot Claim
The mechanistic picture from animal and cell studies is strong. The meta-analysis of 24 preclinical studies showed a tumor remission odds ratio of 25.59 (95% CI 9.08–72.11) — a striking figure with broad confidence intervals that reflect the heterogeneity of animal models. Moving from 24 animal studies to a human RCT is a large step, and that step hasn't been completed for most cancer types.
The human trials that exist — the Phase I/II breast cancer study and the Phase II MDS study — are small, non-randomized in the cancer case series, and focused on immunological endpoints rather than survival outcomes. They show that maitake polysaccharide extracts produce measurable immune changes in humans. They don't show that those changes translate to improved cancer outcomes at the population level. That distinction is real and matters for how the evidence is interpreted.
What the research does support: maitake D-Fraction and MD-Fraction reliably activate specific immune pathways in humans, with a safety profile that makes them reasonable candidates for adjunctive use alongside conventional treatment under medical supervision. The combination data with chemotherapy and trastuzumab is the area most likely to yield meaningful clinical findings in future trials. Explore the broader maitake mushroom benefits or read about maitake's effects on the immune system for more context.
Frequently Asked Questions
What is D-Fraction in maitake mushroom?
D-Fraction is a standardized beta-1,3/1,6-glucan extract isolated from Grifola frondosa. It binds Dectin-1 receptors on immune cells, triggering cytokine production and NK cell activation. In a Phase I/II breast cancer trial, it increased NK T cells by approximately 50% at 10 mg/kg/day, according to research published in the Journal of Cancer Research and Clinical Oncology.
Does maitake D-Fraction have cancer benefits?
Human evidence is preliminary but consistent. MD-Fraction case series data showed symptom improvement or regression in 68.8% of breast cancer patients and 62.5% of lung cancer patients. Combined with chemotherapy, immune-competent cell activity increased 1.2 to 1.4 times over chemotherapy alone. These are observational findings, not randomized trial results.
How does maitake reduce tumor immune suppression?
A 2024 study found that GFP polysaccharide reduced splenic myeloid-derived suppressor cells (MDSCs) from 61.3% to 18.2% in high-dose mice, restoring CD8+ cytotoxic T cell activity at tumor sites. Tumor inhibition rates rose from 22.26% at low doses to 77.65% at high doses, suggesting MDSC elimination is a core mechanism.
Is maitake extract safe to take?
In clinical trials up to 10 mg/kg/day, no serious adverse events were observed. Minor Grade 1 effects included nausea and rash. Two interactions require monitoring: maitake can elevate INR in patients on warfarin and has additive blood-sugar-lowering effects with diabetes medications. Pregnant, lactating, and immunosuppressed individuals should consult a physician.
What's the difference between D-Fraction and whole maitake powder?
D-Fraction and MD-Fraction are standardized extracts containing measurable, concentrated beta-glucan levels. Whole maitake powder delivers significantly lower concentrations of active compounds. The 2002 case series found the combination of whole powder plus MD-Fraction outperformed either alone, suggesting they work through complementary rather than identical mechanisms.
If you want a high-quality maitake extract alongside other immune-supporting mushrooms, the Forest Power Blend includes standardized maitake alongside other functional fungi. For those looking at the full picture of maitake health benefits, immune modulation through D-Fraction and MD-Fraction is where the most rigorous evidence currently sits.